Results 131 to 140 of about 15,165 (218)

Safety of native glucose-dependent insulinotropic polypeptide in humans

In this systematic review, we assessed the safety and possible safety events of native glucose-dependent insulinotropic polypeptide (GIP)(1−42) in human studies with administration of synthetic human GIP.
Helsted, Mads M., Schaltz, Nina L., Vilsbøll, Tina, Christensen, Mikkel B., Knop, Filip K., Gasbjerg, Lærke S.   +5 more
core   +1 more source

Impact of Sleeve Gastrectomy Versus Intensive Lifestyle Modifications With Obesity Management Medications on BMI Trajectory and Target Attainment: A Prospective Matched Cohort Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7126-7136, August 2026.
ABSTRACT Aims To compare sleeve gastrectomy (SG) with intensive lifestyle modification combined with obesity management medications (ILM/OMMs) in adults with severe obesity, focusing on BMI trajectory, time to achieving clinically meaningful weight loss, and metabolic outcomes in a real‐world clinical setting.
Maria Francesca Russo, Giovanni Casella, Giulia Angelini, Sara Russo, James Casella‐Mariolo, Vito D'Andrea, Giulio Illuminati, Lidia Castagneto‐Gissey   +7 more
wiley   +1 more source

Sex Steroids Affect Triglyceride Handling, Glucose-Dependent Insulinotropic Polypeptide, and Insulin Sensitivity

, 2010
OBJECTIVE- To evaluate metabolic effects of sex steroids in nonfasting and fasting conditions, independent from changes in body composition. RESEARCH DESIGN AND METHODS- A randomized clinical trial was performed to create contrasting sex steroid levels ...
Wuyts, B., Kaufman, J.M., Ruige, J.B., Hart, L.M. 't, Lapauw, B., Ouwens, M., T'Sjoen, G., Holst, J.J.   +7 more
core  

A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon-like peptide-1 receptor agonist therapy

Tirzepatide, a novel long-acting glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 (GIP/GLP-1) receptor agonist (GIP/GLP-1 RA), has shown greater clinical efficacy in reducing HbA1c and body weight compared with placebo or selective ...
Pratt, Edward John, Benson, Charles T., Mather, Kieren J., Urva, Shweta, Roell, William C., Haupt, Axel, Knop, Filip K., Rettiganti, Mallikarjuna   +7 more
core   +1 more source

Rates of, Reasons for, and Reactions to Discontinuation of GLP‐1 Receptor Agonists: A Narrative Review

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6533-6549, August 2026.
ABSTRACT GLP‐1RAs are increasingly used for their glucose‐lowering and weight‐management effects, but many patients discontinue them. In this narrative review we aim to review real‐world, quantitative and qualitative GLP‐1RA discontinuation, adherence, and persistence evidence as it aligns with an established conceptual framework for understanding ...
Henry D. Heisey, L. Parker Gregg, Christopher D. Verrico, Dennis T. Villareal, Terri L. Fletcher   +4 more
wiley   +1 more source

Acute GIP and GLP‐1 Administration Exerts Differential Metabolic Effects in Totally Pancreatectomised Individuals

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7280-7290, August 2026.
ABSTRACT Aims While being recognised for stimulating pancreatic insulin secretion, GIP and GLP‐1 exert various extrapancreatic effects relevant in the context of incretin‐based therapies. Here, we evaluated the extrapancreatic effects of GIP and GLP‐1, separately and combined, on postprandial physiology in totally pancreatectomised individuals ...
Liva S. L. Krogh, Maja B. Hansen, Natasha C. Bergmann, Carsten P. Hansen, Bolette Hartmann, Jens J. Holst, Filip K. Knop, Asger B. Lund, Lærke S. Gasbjerg   +8 more
wiley   +1 more source

Short‐Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open‐Label, Randomised Controlled Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7380-7392, August 2026.
ABSTRACT Aims This study aimed to assess the effects of low‐dose tirzepatide combined with metformin (COM) versus metformin (MET) monotherapy in overweight/obese women with polycystic ovary syndrome (PCOS). Materials and Methods Sixty overweight/obese women with PCOS were randomised to the MET group (1000 mg twice daily [BID]) or the COM group (MET ...
Zhuoran Yang, Yuxin Xu, Hu Du, Wenya Liu, Haiyan Chen, Dongfang Liu, Lili Zhang, Cong Wang   +7 more
wiley   +1 more source

Cyclic AMP production and insulin releasing activity of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide

, 2002
Synthetic fragment peptides of glucose-dependent insulinotropic polypeptide (GIP) were evaluated for their ability to elevate cellular cAMP production and stimulate insulin secretion.
Flatt, P.R., Gault, V.A., Harriott, Patrick, O'Harte, F.P.M.   +3 more
core  

Tirzepatide‐Induced Functional Small Bowel Obstruction in a Surgically Naïve Patient: A Case Report

Clinical Case Reports, Volume 14, Issue 7, July 2026.
ABSTRACT Tirzepatide dose escalation may precipitate functional small bowel obstruction that mimics mechanical obstruction, even in surgically naïve patients. Careful medication review and objective tools such as the water‐soluble contrast challenge can support safe non‐operative management and help avoid unnecessary surgical intervention.
Takuto Shimada, Yoshihiro Nose, Hiroki Tojima, Takahiro Maehata, Akitoshi Kato   +4 more
wiley   +1 more source

Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 4, July 2026.
Tirzepatide 15 mg and cagrilintide–semaglutide (CagriSema) achieve the greatest percent body weight reduction (−17.97% and −17.46%, respectively) and the highest rates of ≥ 20% weight loss versus placebo in this network meta‐analysis of 25 randomized trials.
Sultan Hamarsheh, Abdel Rahman Jaber, Omar Abu‐Khazneh, Celina R. Andonie, Saleem Majadleh, Anwar Zahran, Hazem Ayesh   +6 more
wiley   +1 more source